ROIV - Immunovant stock rallies for second day fueled by public offering drug data
2023-09-27 10:29:47 ET
More on Immunovant
- Immunovant: Immune Boost, From Clinical Trials To An Aggressive Bullish Stock
- Immunovant: Data Sizzles, But The Steak Isn't Done Yet (Rating Upgrade)
- Immunovant, Inc. 2023 Q2 - Results - Earnings Call Presentation
- Immunovant announces proposed offering of $300M of common stock
For further details see:
Immunovant stock rallies for second day, fueled by public offering, drug data